000843846 000__ 06960cam\a2200565I\\4500
000843846 001__ 843846
000843846 005__ 20230306144817.0
000843846 006__ m\\\\\o\\d\\\\\\\\
000843846 007__ cr\|n\nnnunnun
000843846 008__ 180707s2018\\\\si\\\\\\ob\\\\000\0\eng\d
000843846 019__ $$a1043656333$$a1043696045
000843846 020__ $$a9789811067907$$q(electronic book)
000843846 020__ $$a9811067902$$q(electronic book)
000843846 020__ $$z9811067899
000843846 020__ $$z9789811067891
000843846 035__ $$aSP(OCoLC)on1043429230
000843846 035__ $$aSP(OCoLC)1043429230$$z(OCoLC)1043656333$$z(OCoLC)1043696045
000843846 040__ $$aYDX$$beng$$cYDX$$dN$T$$dFIE$$dOCLCO$$dN$T$$dEBLCP$$dUAB$$dOCLCA
000843846 049__ $$aISEA
000843846 050_4 $$aHD9672.I52
000843846 08214 $$a338.4/73621$$223
000843846 1001_ $$aMitsumori, Yaeko,$$eauthor.
000843846 24514 $$aThe Indian pharmaceutical industry :$$bimpact of changes in the IPR regime /$$cYaeko Mitsumori.
000843846 260__ $$aSingapore :$$bSpringer,$$c[2018]
000843846 300__ $$a1 online resource.
000843846 336__ $$atext$$btxt$$2rdacontent
000843846 337__ $$acomputer$$bc$$2rdamedia
000843846 338__ $$aonline resource$$bcr$$2rdacarrier
000843846 4901_ $$aSpringerBriefs in health care management and economics
000843846 504__ $$aIncludes bibliographical references.
000843846 5050_ $$aIntro; Contents; Chapter 1: Introduction; 1.1 Background; 1.2 Trend of Indian Pharmaceutical Industry and Indian Patent Policies; 1.2.1 Trend of Indian Pharmaceutical Industry; 1.2.2 TRIPS Enforcement and Background to Introduction of Product Patents; 1.2.3 Discussion around Introduction of Product Patents into the Indian Patent Regime; 1.3 Research Subject and Objectives of This Study; References; Chapter 2: Historical Background and Current Status of Indian Pharmaceutical Industry and Indian Patents Regime; 2.1 Status of the Indian Pharmaceutical Industry
000843846 5058_ $$a2.2 Remarkable Features of the Pharmaceutical Industry from the Perspective of Patent Protection2.3 Current Status of the Indian Pharmaceutical Industry; 2.3.1 Indian Pharmaceutical Companies vs. Foreign Pharmaceutical Companies; 2.3.2 Disease Profile in India; 2.3.3 Regulation of Drugs in India; 2.3.4 Medicines Purchasing Trend; 2.3.5 Advanced Technology in the Indian Pharmaceutical Industry; 2.3.6 Development of the Indian Pharmaceutical Industry; 2.4 Indian Patent Law; 2.4.1 Transition of Indian Patent Law; 2.4.2 Section 3 (d) of Patents (Amendment) Act, 2005 of India; 2.4.3 Mailbox
000843846 5058_ $$a2.4.4 EMRReferences; Chapter 3: Research Subject and Methodology; 3.1 Setting up a Hypothesis; 3.2 Hypothesis; 3.3 Research Subject and Methodology; 3.4 Research Framework; References; Chapter 4: Analysis of Preceding Studies; 4.1 Developing Countries and Patent Law; 4.2 Impact of Introduction of Product Patents; 4.3 Section 3 (d) of Indian Patents (Amendment) Act, 2005; 4.4 Transition of Indian Pharmaceutical Industry Business Model; 4.5 Working Hypothesis; References; Chapter 5: Analysis of Indian Pharmaceutical Industry Indicators: Data Analysis; 5.1 Data Analysis Methodology
000843846 5058_ $$a5.2 Indian Pharmaceutical Companies Stock Price Analysis5.3 Business Performance Analysis of Indian Pharmaceutical Companies: Trend of Sales and Profits; 5.4 Trend of R&D Investment in Indian Pharmaceutical Industry; 5.5 Development Pipeline Analysis; 5.6 Analysis of Patent Applications in India; 5.7 An Analysis of Medical Products Trade (Bulk/Intermediates and Formulations); 5.8 Development Model of Indian Pharmaceutical Industry; 5.9 Summary of This Chapter; References; Chapter 6: Analysis of Patents Act Enforcement After Introduction of Product Patents
000843846 5058_ $$a6.1 Method of Analysis: Outlines of On-Site Interviews in India6.1.1 Pharmaceutical Industry Associations; 6.1.2 Pharmaceutical Industry in India; 6.1.3 Indian Government; 6.1.4 Universities; 6.1.5 Law Firms and Consulting Firms; 6.2 Views of Pharmaceutical Industry and the Indian Government; 6.2.1 IDMA; 6.2.2 IPA; 6.2.3 OPPI; 6.2.4 CSIR; 6.3 Patent Rejection Based on Section 3 (d); 6.3.1 Patent Rejection for Gleevec; 6.3.2 Roche vs. Cipla over Tarceva; 6.4 Monetization of R&D Outcomes; 6.4.1 New Subsidiaries for New Drug Discovery/Development; 6.4.2 Out-Licensing; 6.4.3 Drug Delivery Systems
000843846 506__ $$aAccess limited to authorized users.
000843846 520__ $$aThis study analyzes the impact of the revision of the Indian Patent Act (2005) on the Indian pharmaceutical industry, which has been achieving healthy growth over the past 30 to 40 years or more. As of 2005, the Indian pharmaceutical industry was ranked as No. 4 in the world in terms of volume and 15th in terms of value. WTO/TRIPS required India to revise its patent law, however, and to introduce product patents in the pharmaceutical field. Many not only in India but also in the world had argued that the local pharmaceutical industry could deteriorate once a strong patent law (such as a product patent) was introduced. However, the Indian pharmaceutical industry has continued to develop rapidly even after the revision of the patent law in 2005. This present study started with efforts to work out the reason the Indian pharmaceutical industry successfully expanded even after the introduction of product patents. The study found that a unique article (the so-called '3-d') inserted in the Patent Act 2005  might have played a role in diminishing or preventing a negative impact from the introduction of a strong patent system, such as a product patents.  The study also considers that a change of the business model adopted by the Indian pharmaceutical industry might have contributed to diminishing the effect of the negative impact from the introduction of a strong patent law. This study also covers recent developments in India regarding intellectual property rights and the pharmaceutical industry. One is India's very first compulsory license granted to an Indian pharmaceutical company, Natco, against the large German pharmaceutical firm Bayer; and the second is the Supreme Court decision on Novartis' Gleevec. The study analyzes the fundamental problems that caused these two events: access to medicine and gaps in the concept of intellectual property in the pharmaceutical industry. As possible solutions to these fundamental issues, this book explores the ideas of voluntary licensing and tiered pricing. .--$$cProvided by publisher.
000843846 588__ $$aOnline resource; title from PDF title page (viewed July 13, 2018).
000843846 650_0 $$aPharmaceutical industry$$zIndia.
000843846 650_0 $$aPatent laws and legislation$$zIndia.
000843846 650_0 $$aIntellectual property$$zIndia.
000843846 650_0 $$aMedical economics.
000843846 650_0 $$aGlobalization.
000843846 77608 $$iPrint version:$$z9811067899$$z9789811067891$$w(OCoLC)1004126431
000843846 830_0 $$aSpringerBriefs in health care management and economics.
000843846 852__ $$bebk
000843846 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-981-10-6790-7$$zOnline Access$$91397441.1
000843846 909CO $$ooai:library.usi.edu:843846$$pGLOBAL_SET
000843846 980__ $$aEBOOK
000843846 980__ $$aBIB
000843846 982__ $$aEbook
000843846 983__ $$aOnline
000843846 994__ $$a92$$bISE